A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
← catalyst calendarSponsored by Crinetics Pharmaceuticals Inc. (industry) · CRNX — their whole pipeline →.
Phase
Phase 2
Status
Terminated
Study type
Interventional
Design
Na · None · Treatment
Enrollment
43actual
Sites
22
Countries
Brazil, Germany, Greece +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Why the sponsor stopped it
The study was stopped early for business reasons (not due to changes in the benefits or risks of paltusotine).
As filed on the registry record, in the sponsor's own words.
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2020-01-29 | actual | When the study began enrolling |
| Primary completion | 2026-06-30 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-06-30 | actual | The whole study's end, after follow-up |
| First posted | 2020-02-10 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-29 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Acromegaly
Intervention
- Drug: Paltusotine — also filed as CRN00808
Primary outcome
what the primary-completion date above is the date OFIncidence of treatment-emergent adverse events (TEAEs) throughout the study
measured Week 316
Permalink · CRNX's whole pipeline · Catalyst calendar · Every registered study · What changed